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Exosomes are nano vesicles from the larger family named Extracellular Vesicle (EV)s
which are released by various cells including tumor cells, mast cells, dendritic cells,
B lymphocytes, neurons, adipocytes, endothelial cells, and epithelial cells. They are
considerable messengers that can exchange proteins and genetic materials between
the cells. Within the past decade, Tumor derived exosomes (TEX) have been emerged
as important mediators in cancer initiation, progression and metastasis as well as host
immune suppression and drug resistance. Although tumor derived exosomes consist
of tumor antigens and several Heat Shock Proteins such as HSP70 and HSP90 to
stimulate immune response against tumor cells, they contain inhibitory molecules like
Fas ligand (Fas-L), Transforming Growth Factor Beta (TGF-β) and Prostaglandin E2
(PGE2) leading to decrease the cytotoxicity and establish immunosuppressive tumor
microenvironment (TME). To bypass this problem and enhance immune response, some
macromolecules such as miRNAs, HSPs and activatory ligands have been recognized
as potent immune inducers that could be used as anti-tumor agents to construct a
nano sized tumor vaccine. Here, we discussed emerging engineered exosomes as a
novel therapeutic strategy and considered the associated challenges.
Keywords: cancer immunotherapy, tumor derived exosomes, engineered exosomes, immunomodulatory
therapies, immunosuppression
INTRODUCTION
Although cancer immunotherapy has been stablished as a promising treatment option, it faces
many challenges including the lack of recognition of specific tumor-associated antigens by the
immune system, in part due to the presence of thymic tolerance to self-antigens. Moreover,
the cancer microenvironment has immune suppressive properties, thus reducing responses to
immune-mediated attacks against the cancer. Tumor microenvironments consist of many cell
types that become educated and adapted to support primary tumor growth. Of note, tumor
derived exosomes might be involved in this process. In this review, we discuss the role of Tumor
derived exosomes in the associated immune suppression and the potential therapeutic applications
of modified Tumor derived exosomes, which represents a novel approach for development of
therapeutic cancer vaccines.
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GRAPHICAL ABSTRACT | Imbalance between immune suppression and immune response by tumor derived exosomes. Potential role of engineered tumor derived
exosomes in changing the fate of immune response. Image designed by Adeleh Taghikhani.
TUMOR DERIVED EXOSOMES (TEXs)
Exosomes are small vesicles (30–120 nm) that are derived from
various cells within late endosomes. They are released into the
microenvironment where they play a major role in cell-cell
communication (1, 2). Exosomes were first considered as waste
vesicular bodies of reticulocytes in process of maturation to
erythrocytes (3). Moreover, recent experiments support the idea
of exosomes could maintain cellular homeostasis (4).
They are generated by inward budding of multivesicular
bodies (MVBs) (5), while the exact mechanism of exosome
entry into the target cell is not yet clear, phagocytosis and
fusion are potentially involved (6, 7). Exosomes are secreted by
various cells. For the first time, their release was reported more
than 40 years ago as platelets sprinkles (8). Immune cells and
cancer cells are also recognized as exosome producers (9–12).
Regarding the membrane lipid content, exosomes contain higher
concentrations of sphingolipids and cholesterol than that of the
cell of origin. They also contain soluble and surface proteins
as well as mRNAs and miRNAs. mRNAs result in production
of proteins in target cells and miRNAs are transferred between
cells and affect expression of different genes (13). Proteomics
analysis showed that tumor-derived exosomes (TEXs) contain
major histocompatibility complex (MHC) molecules, heat shock
proteins, and tetraspanin (CD63, CD81 and CD9) which
are known as endosomal pathway proteins. Moreover, tumor
antigens such as Mart1, gp100, TRP, and Her2-neu have been
found in TEXs (9, 14); (Figure 1). Cancer cells subjected
to hypoxic conditions play a role in promoting angiogenesis
and metastasis by releasing potent angiogenic factors. They
home to metastatic areas through the induction of molecular
signals involved in tumor cell recruitment, extracellular matrix
deposition, and vascular proliferation. It was also shown that
some TEXs contain surface TGF-β along with betaglycan,
which could trigger SMAD-dependent signaling and regulate the
differentiation of fibroblasts to myofibroblasts (15). In addition,
TEXs protect cancer cells from apoptosis through the selective
efflux of the apoptosis inducer proteins, which are presented
by effector cells such as T cells or natural killer (NK) cells.
Moreover, TEXs might diminish the effects of therapy via drug
efflux or by masking the binding site of monoclonal antibodies;
this could promote the emergence of chemotherapy-resistant cell
populations (16).
Biogenesis of Exosomes
Exosome biogenesis begins with the production of endocytic
vesicles via the internalization of surface lipids and clathrin-
dependent or independent endocytosis. These vesicles can form
early endosomes and late endosomes. Exosomal secretion is
achieved by attaching MVBs (microvesicular bodies) to the cell
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FIGURE 1 | Structure of tumor derived exosome. Size and composition of TEXs. Image designed by Adeleh Taghikhani.
membrane, which appears to be dependent on a variety of Rab
GTPase proteins and endosomal sorting complex required for
transport (ESCRT). The ESCRT system assists in the sorting of
endosomal ubiquitinated proteins for secretion in nanoparticles
such as exosomes (17–19).
Isolation and Characterization
Differential ultracentrifugations have been considered as a gold
standard method for effective isolation of extracellular vesicles
from conditioned medium which is based on size. In this method,
microvesicles, the vesicles which are larger than exosomes,
are pelleted at 10,000–20,000 × g and the supernatant is
subjected to a second centrifugation step at 100,000 × g, which
results in the isolation of exosomes that are typically smaller
than microvesicles.
Other methods for exosome isolation include immunoaffinity
purification (affinity chromatography), size exclusion
chromatography, polymeric precipitation, microfluidics,
and commercial kits based using columns or polymeric
precipitations. Exosomes are characterized using a range of
techniques including electron microscopy, nanoparticle tracking
analysis, dynamic light scattering, flow cytometry and western
blotting (20–23). Evidence has shown that the formation of
EVs requires function of the endosomal sorting complex
required for transport (ESCRT). The typical exosomal protein
Alix, which is associated with several ESCRT (TSG101 and
CHMP4) proteins, has been reported to participate in endosomal
membrane budding as well as exosomal cargo selection therefore
these molecules selected as exosomal specific markers in their
characterization (24).
IMMUNOSUPPRESSIVE EFFECTS
OF TEXs
Tumor-derived exosomes can carry immunosuppressive
molecules such as FasL, TGF-β1, TRAIL, PD-L1, and NKG2D
ligands, which are involved in suppression of the immune
response (Table 1).
Expression of FasL, PD-L1, and TRAIL by
TEXs
FasL, TRAIL (TNF-related apoptosis-inducing ligand) and PDL1
(Programmed death-ligand 1) are known as regulator of immune
cells homeostasis and activity through inducing of apoptosis
following receptor/ligand interactions. The tumor exosome
surface may present these regulatory factors to inhibit T-cell
proliferation and response through the induction of apoptosis
in a dose-dependent manner. This effect can be blocked by the
antibody-mediated inhibition of FasL binding to its receptor (25–
27). Exosomes isolated from patients with ovarian cancer could
express MHC I, placental alkaline phosphatase, TRAIL, and FasL.
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TABLE 1 | Tumor-derived exosomes involved in suppression of the immune
response.
Immunosuppressive
molecule
Function References
Fas-L, placental
alkaline phosphatase,
B23/nucleophosmin
T cell apoptosis (28)
Fas-L CD8 + T cell apoptosis (25)
Fas-L Induction of receptor and
mitochondrial apoptotic pathways
in Jurkat and activated T cells.
(26)
TGF-β Differentiation to myofibroblast (15)
TGF-β T cell suppression (29)
NKG2D-L NK cell suppression (32)
NKG2D-L NK cell down regulation (33)
BAG6, BAG4 Tumor evasion (35)
ND Treg induction (39)
ND Treg induction (40)
PGE2 and TGF-β Induction of MDSC expressing
Cox2, IL-6, VEGF and arginase-1
(78)
STAT3 MDSC induction (41)
IL-6 Blockade of DC differentiation (43)
RIG1 and STAT1 Therapy resistancy (44)
PGE2 DC dysfunction (42)
Upregulation of
inhibitory genes
Functional decline in T cells (37)
TGF-β and PD-L1 Drug resistance (30)
ND, not defined.
These exosomes also could suppress the activatory signals of T
cells (CD3z and JAK3) following the incubation of TEXs with
Jurkat T cells for 48 h (28).
Expression of TGF-β by TEXs
Transforming growth factor-β1 in exosomes has been proposed
to mediate some immunosuppressive effects of TEXs. The
presence of TEXs in the monocyte differentiation environment
leads to the production of HLA-DR−/low CD14+ cells. TGF-
β secretion by CD14+ HLA-DR− subsets was significantly
increased in peripheral blood mononuclear cells isolated from
melanoma patients compared to that from healthy subjects (29).
It was shown that TEXs might modulate fibroblast phenotype
and function via exosomal TGF-β. The mechanism associated
with TGF- β exosomal delivery is not limited to SMAD-related
pathways, as it was also shown that betaglycans can accompany
TGF-β1 on the exosome surfaces, which could facilitate the effects
of TGF- β (15). HER2 targeted drug resistance is correlated
with TGF-β1 and PDL-1 levels in tumor-derived exosomes.
Furthermore, exosomes that carry these molecules could result
in adaptation by other drug sensitive cells (30).
Expression of NKG2D Ligand/BAG6
by TEXs
It was shown that exosomes from murine mammary cell lines can
inhibit NK cell cytotoxicity (31). NKG2D is normally expressed
on the surface of NK, NKT, activated CD8+, and γδ T cells, and
its down-regulation in tumor cells is a key mechanism through
which cells evade immune surveillance. NKG2D ligands (induced
self-proteins) are normally absent on the surface of cells, whereas
they are up-regulated in cancers. NKG2D ligands and soluble
growth factors including tumor cell secreted TGF-β1 might affect
the expression of NKG2D. In NK cells, NKG2D itself is able to
trigger cytotoxicity, whereas the function of NKG2D in CD8+ T
cells is to send co-stimulatory activating signals. In exosome
studies, it was found that NKG2D ligands or TGF-β1 on the
surface of exosomes can down-regulate NKG2D receptors on
effector cells. NKG2D ligands and TGF-β1 expression might
affect CD8+ T cells and NK cell activity by reducing NKG2D
expression on these cells. It is obvious that TEXs harboring a
ligand for NKG2D that interacts with lymphocytes do not activate
CD8+ T cells or NK cells (32).
Blocking ULBP1-5 and MIC A/B in TEXs increases the
expression of NKG2D indicating that NKG2D ligand expression
in TEXs inhibits NKG2D expression on the surface of NK cells
and CD8+ T cells, which leads to the suppression of their in vitro
and in vivo loss of function (33, 34). Although, NKG2D ligands
on the surface of TEXs were shown to block the activating role
NKG2D, one of the NKP30-ligands named BAG6 was expressed
on the surface of TEXs and as a soluble molecule; it was sown
that the soluble form could promote tumor cell resistance to NK-
mediated cytotoxicity, whereas the exosomal form triggered NK
cell activation (35).
Although most of experiments have explained the
immunosuppressive effects of TEXs on diverse immune
cells, they revealed that these structures can provide tumor
antigens and heat shock proteins such as HSP70 on their surface
which could induce protective anti-tumor immune responses.
Gastper et al. 36 suggested that natural killer (NK) cells was
stimulated selectively by Hsp70/Bag-4 surface-positive exosomes.
Induction of Treg Population by TEXs
Tumor derived exosomes can serve as the vehicle responsible for
inducing changes in mRNA expression levels in T cells through
their miRNA content (37). Human T cells co-incubated with
TEXs or exosomes isolated from the plasma of patients with
cancer were shown to down-regulate CD3ζ and JAK3 expression
in primary activated T cells and mediate the Fas/FasL-mediated
apoptosis of activated CD8+ T cells. TEXs also promote the
proliferation of CD4 + T conventional and their conversion
to CD4+CD25highFOXP3+CD39+ Tregs, which co-express IL-
10 and TGF-β, CTLA-4, and granzyme B/perforin (27, 37)
and regulate ADO production by delivering CD73 to the
Tregs (38). Thus, TEXs effectively mediate immune suppression.
TEXs also increase TGF-β1-associated phospho-SMAD2/3 and
phospho-STAT3 levels and IL-10 expression in Tregs (39). T
cell response to TEXs is related to surface signaling rather
than internalization. Signaling might trigger Ca2+ influx or
adenosine/A2A R reactions. Recent studies suggest that Tregs are
potently induced by these pathways, in contrast to that observed
for CD8+ or CD4+ conventional T cells. This confirms that
TEXs could regulate efficient crosstalk between tumor cells and
Tregs, which might regulate the tumor environment and immune
responses (40). In Tregs, TEXs-mediated down-regulation of
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genes related to the adenosine pathway results in high expression
of CD39 and CD73, as well as increased adenosine production.
TEXs also induce the up-regulation of inhibitory genes in CD4+
T conv cells, which results in the loss of surface CD69 and
a functional decline. Tumor exosomes are not internalized by
T cells, but signaling molecules that they carry and deliver to
cell surface receptors modulate gene expression and functions
in human T lymphocytes. Moreover, TEXs not only induce
differentiation and increase expansion of Tregs but also enhance
their resistance to apoptosis (39).
Induction of Myeloid-Derived Suppressor
Cell (MDSC) by TEXs
Myeloid-derived suppressor cells have been identified in both
human and mouse peripheral blood as a population of
immature cells with the ability to suppress T-cell activation.
Their accumulation in tumor-bearing mice and human cancer
patients was shown to contribute to the development of cancer.
Chalmin et al. (41) isolated exosomes from a mouse tumor
cell line and demonstrated that the interaction between heat
shock protein 72 (HSP72) on the surface of exosomes and the
suppressive activity of MDSCs was mediated by the activation
of STAT3. In addition, soluble factors derived from tumors
increase MDSC induction through Erk pathway activation.
HSP72 on the TEXs surface activates STAT3 in MDSCs through
TLR2/myd88 and the autocrine production of IL-6. At the
molecular level, HSP72 in TEXs, which can act as a ligand of
TLR2 in MDSCs, is responsible for the activation of MDSCs
and their immune repressive ability. The production of TEXs
was decreased using dimethyl amiloride, a drug used to treat
high blood pressure, and in vivo efficiency of the anti-tumor
drug cyclophosphamide was increased in three different mouse
tumor models. Overall, the findings in both human and
mouse cell lines indicate that HSP72 expression on the surface
of TEXs might prevent tumor recognition by the immune
system (41).
Inhibition of DC Differentiation by TEXs
Tumor derived exosomes can target CD11b+ myeloid precursors
in vivo, in mice. Moreover, TEXs prevent the differentiation
of mouse myeloid progenitor cells into dendritic cells (DCs)
in vitro. The addition of TEXs on the 1st day of in vitro
culture was shown to significantly inhibit the differentiation
of monocytes into DCs (42). Similarly, human TEXs inhibit
monocyte differentiation in vitro. IL-6 and phosphorylated
STAT3 levels were increased 12 h after stimulating myeloid
precursors cells with TEXs. Moreover, TEXs were less effective
in blocking the DC differentiation of monocytes isolated from
the bone marrow (BM) of IL-6 knockout mice. The addition
of rIL-6 to IL-6 knockout BM cell cultures alleviated this
inhibition, restoring DC differentiation. These data indicate
that IL-6 from the TEXs plays a major role in blocking the
differentiation of BMDCs. Mouse myeloid progenitor cells can
take up exosomes and undifferentiated myeloid progenitor cells
accumulate in the mouse spleen; subsequently, the differentiation
of DCs was found to be inhibited. Although a small number of
myeloid progenitor cells can be generated in vitro after treatment
with myeloid DC exosomes, these cells do not mature and
lose their ability to stimulate T-cell activation. Taken together,
these results indicate that TEXs-mediated inhibition of DC
differentiation might be one of the major mechanisms through
which tumor cells evade the immune response, representing a
major obstacle for the successful application of immunotherapy
to treat cancer (43).
Other Immunosuppressive Mechanisms
of TEXs
Contact between stromal and cancer cells can affect the response
to treatment. Boelens et al. (44) showed that the stromal and
breast cancer cells utilize paracrine and juxtacrine signaling
to acquire resistance to chemotherapy and radiotherapy. The
transfer of exosomes from stromal cells to breast cancer cells
during their interaction was also demonstrated. RNA species in
exosomes, which are largely non-coding elements, stimulate RIG-
I receptors and activate STAT1 signaling. In parallel, stromal cells
activate NOTCH3 in breast cancer cells. Therefore, stromal cells
use exosomes to stimulate and orchestrate signaling in breast
cancer cell subpopulations to acquire resistance to treatment and
mediate tumor recurrence (44).
Although these findings explain the immunosuppressive
effects of TEXs on diverse immune cells, they also suggest
that these structures can provide tumor antigens for antigen
processing cells and enhance the chances of tumor antigen
recognition by immune cells. Dendritic cells pulsed with TEXs
can prime cytotoxic T cells to induce protective anti-tumor
immune responses. Furthermore, high levels of Hsp70 in
TEXs were reported to elicit a direct Th1-polarized immune
response. In addition, NK and NKT activation by TEXs was also
reported (36, 45).
STRATEGIES FOR INCREASING
IMMUNOSTIMULATORY EFFECTS
OF TEXs
According to the aforementioned results, it seems that
appropriate responses from the host against TEXs will only
be induced by engineering them; accordingly, several studies
have been conducted and their results are proof of this claim.
Here, we discuss strategies devised over the past few years to
circumvent this problem, immunosuppressive properties of
TEXs, along with their possible applications and limitations.
Genetic Engineering
Tumor derived exosomes could be manipulated by tumor-
associated genes or some known immune boosters such as
CpG DNA and TLR ligands and overexpress them to induce
cellular and innate immunity; they could also be targeted using
genetic materials such as siRNA, which can be introduced by
electroporation into purified exosomes. Using this approach,
nerve cells were previously targeted and gene silencing was
confirmed (46). As a novel vaccine for cancer therapy, exosomes
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secreted by B16 melanoma cells modified to express both
tumor-associated antigens and the pathogenic antigen, which
increased cellular immunity against Mycobacterium tuberculosis
and resulted in suppression of tumor growth in tumor-
bearing mice (47). Moreover, streptavidin and lactadherin
expressing exosomes (SAV-exos) used in combination with
biotinylated CpG DNA and immunization with CpG-SAV-
exos resulted in strong anti-tumor effects in tumor-bearing
mice (48).
miRNA Modification
Exosomes secreted from cell lines that were treated with DHA
(docosahexaenoic acid) were shown to express higher levels of
let-7a, miR-23b, miR-27a/b, miR-21, let-7, and miR-320b, which
are tumor suppressor miRNAs. Further untreated epithelial cells
incubated with the exosomes are also shown to have increased
levels of those miRNAs. The data showed that DHA, as an anti-
angiogenic factor, can affect miRNA levels in tumor exosomes.
Therefore, we could target exosome signaling between tumor
cells in the cancer microenvironment (49). Also, we found that
Let-7i and miR-142 upregulation in TEX have notably enhancing
effect on either DC maturation or CTL induction and cytokine
release (50).
Moreover, ultra-filtered exosome lysates (UELs), which can
be prepared for the depletion of miRNAs from exosomes,
were assayed and the resulting protein extraction was used
for dendritic cell activation. The results indicate that miRNA-
depleted TEXs proteins might be promising agonists for the
specific activation of DCs (51).
Conjugation
The binding of some molecules triggers immune cells to naturally
become potent effectors. Furthermore, the binding of such
activator ligands or co-stimulators to TEXs might increase their
effectiveness in difference processes such as attaching to TLR
ligands like CpG-DNA, Poly:IC and IL15Rα or activation of
NK cells by using NKG2D ligands. Since, exosomes produced
by immature monocyte derived DC naturally present Bat3 and
nkp30 ligands on their surface, leading to diminished NK cell
responses (52).
In addition, we should mention another opportunity;
VAR2CSA is a malarial protein that can bind the VAR2CSA-
ligand or chondroitin sulfate (CS) expressed in the placenta. CS
is also present on a high proportion of malignant cells and could
be targeted by recombinant VAR2CSA (rVAR2). Salanti showed
that this rVAR2 could bind placental-type CS as well as tumor
cells (PC-3, MDA-MB-231, and MyLa2059). They proposed that
targeting the common CS chain, which is present on different
cancer cells, might offer a novel cancer treatment strategy (53,
54) furthermore, VAR2CSA upregulated TEXs could be the next
level of this vaccination procedure.
The use of exosomes for protein loading via optically
reversible protein–protein interactions (EXPLORs) is a new
strategy that was described for the intracellular delivery of
target proteins. This occurs through the integration of a
protein–protein interaction module that is controlled by blue
light during endogenous exosome biogenesis (55). It has also
been shown that the IFN gamma and its target gene, IRF-l has
important role in tumor cell apoptosis. TEXs released from IRF-
1 primed cells containing increased level of IL-15R and MHC-I
and could promote antitumor immunity by CD4+ and CD8+ T
cells infiltration (56).
HSP70/90 Overexpression (Heat
Treatment)
It has been shown that exosomes isolated from tumor cells
express heat shock proteins including the cognate 71-kDa
HSP, the 70-kDa HSP4, and HSP90 alpha and beta on their
surfaces (57). Moreover, tumor-derived chaperon rich cell lysates
containing Hsp70, Hsp90, calreticulin, and glucose-regulated
protein 94 have been reported to activate DCs (58). Bu
et al. (59) demonstrated that exosomes from DCs loaded with
chaperone-rich cell lysates could elicit a potent T cell immune
response against intracranial glioma in mice. These findings
suggested that chaperons are potent candidates to increase the
immunostimulatory effect of TEXs.
Lipid Modification and Glycosylation
Hybrid exosomes, which are developed by fusing their
membranes with liposomes (60–62), can be combined with
genetic modification techniques. The interactions between the
engineered exosomes and cells could be modified by changing
the lipid composition or the properties of the exogenous
lipids, which was shown to facilitate drug delivery or antigen
presentation to immune cells located in the lymph node (62)
and delivered CRISPR/Cas9 system in Mesenchymal Stem cells
(MSCs) to alleviate in vivo gene editing (63). Glycosylation
was identified as a promising strategy for stabilizing peptides
on the surface of exosomes; this was shown to protect them
from proteolytic degradation and effectively direct exosomes to
specific destinations in vivo. This strategy could enhance the
display of targeting peptides and generally enable and improve
exosome-based therapeutics (64).
Future Vesicle-Based Cancer Therapies
As drug delivery vehicles, exosomes could be used for carrying
various hemotherapeutic agents. Curcumin (natural polyphenol
compound) which its anti-inflammatory effect have been shown
in several studies (65–67) was packed in exosomes to enhance
curcumin effectiveness (68, 69). Paclitaxel, doxorubicin, and
temozolomide could be packed into exosomes. siRNAs or anti-
miRNA oligonucleotides might also be used as therapeutic
cargos carried by exosomes (70). Moreover, novel technologies
like nanoparticles (cationic liposomes) containing tumor RNAs,
known as RNA lipoplexes (RNA-LPX), have been established.
These RNA-LPXs were shown to induce immune responses (71–
74). An in vivo study using intravenous vaccination demonstrated
the homing of RNA-LPXs to lymphoid tissues and stimulation
of macrophages and DCs, which promoted T cell responses
via IFN-α release and Th1 and CD8+ polarization (72). MSCs
are particularly interesting as they localize and migrate toward
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damaged and inflammatory microenvironments including solid
tumors, however they display multi-functional activities with
both pro- and anti-tumor effects within the microenvironment;
thus, MSC-derived exosomes could represent a potential anti-
tumor vaccine (75) or drug delivery strategy (76, 77).
CONCLUSION
As discussed, TEXs play a major role in tumor immune
evasion and growth. In addition, they protect tumor cells
from chemotherapy and immunotherapy via the efflux
the chemicals and the masking of monoclonal antibody
binding sites. TEXs, comprising a critical part of the tumor
microenvironment, have been proposed as markers for the
early diagnosis of cancers. Although evidences suggest that
we should target TEXs for cancer treatment, it might be
time to address this from a different point view. Based
on data that we described herein, we suggest that tumor
derived extracellular vesicles could be manipulated and provide
cancer treatment. In this way, tumor-associated antigens,
unrecognized antigens in the cytosol of TEXs, and other
molecules such as HSPs could be exploited in the future for
cancer treatment.
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